MARKET

CRDL

CRDL

Cardiol Therapeu
NASDAQ
1.360
+0.010
+0.74%
After Hours: 1.360 0 0.00% 16:10 05/13 EDT
OPEN
1.340
PREV CLOSE
1.350
HIGH
1.400
LOW
1.339
VOLUME
497.79K
TURNOVER
--
52 WEEK HIGH
1.710
52 WEEK LOW
0.8800
MARKET CAP
152.07M
P/E (TTM)
-4.7989
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)
TipRanks · 1d ago
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position
TipRanks · 2d ago
Weekly Report: what happened at CRDL last week (0504-0508)?
Weekly Report · 2d ago
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
TipRanks · 6d ago
Cardiol Therapeutics says Phase II CardiolRx recurrent pericarditis results set for JAHA publication
PUBT · 6d ago
Stocks in play: Cardiol Therapeutics Inc.
Barchart · 6d ago
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Cardiol Therapeutics (CRDL) and Vertex Pharmaceuticals (VRTX)
TipRanks · 05/05 13:10
Weekly Report: what happened at CRDL last week (0427-0501)?
Weekly Report · 05/04 10:10
More
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Webull offers Cardiol Therapeutics Inc stock information, including NASDAQ: CRDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDL stock methods without spending real money on the virtual paper trading platform.